GBIM:OTCMKTS
GlobeImmune Inc
US$0.00010
0.00%
(0.00) 1D
9월 29일, 오후 3시 48분 52초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoGBIM의 주요 통계 생성 중...
시가총액
580.00
평균 거래량
1.74천
거래량
0.00
52주 최고가
US$0.04
52주 최저가
US$0.00
유통 주식수
575.20만
직원 수
22
시가총액
580.00
평균 거래량
1.74천
거래량
0.00
52주 최고가
US$0.04
52주 최저가
US$0.00
유통 주식수
575.20만
직원 수
22
뉴스 기사
웹 소스 및 뉴스 파트너 제공
경북매일
·
11분 전
美 물가 충격에 기술주 ‘흔들’…나스닥 1.88% 급락
네이버 프리미엄콘텐츠
·
19시간 전
10월 14일 미국 경제 뉴스: 지수는 제자리, 은행 실적에서 읽을 변화
블루밍비트
·
4시간 전
뉴욕증시, 하락세로 전환…나스닥 1.65%↓
프로필
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc에 관한 정보